Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3609_Библиотеки_им_академика_М_И_Перельмана
.pdf
Atherectomy andCalcium-Modifying
https://t.me/medicina_free
Devices
NarayananThulasidasan andPanosGkoutzios
19
Case Presentation
A 72-year-old male patient presenting with chronic limbthreatening ischaemia of the right lower limb evidenced by
tissue loss (Rutherford category 5) was imaged with CT
angiography and found to have a short ush proximal SFA
occlusion, signicant stenotic disease in the distal SFA and
two-vessel run-off to the foot via the peroneal and posterior
tibial arteries. The proximal SFA occlusion was composed of
heavily calcied plaque with a “coral-reef” appearance. The
patient was deemed a poor candidate for surgical bypass due
to severe chronic obstructive pulmonary disease, and therefore an endovascular procedure under local anaesthesia and
sedation was proposed.
Continued at page 188
Background
The initial generation of atherectomy devices were developed in the 1980s with the aim of providing an endovascular
analogue to traditional open surgical endarterectomy. The
earliest English-language publication of a rst-in-human
series of atherectomy procedures was in 1988, [1] where 21
patients were treated using the Simpson atherectomy catheter. Over the ensuing 34years multiple atherectomy devices
have been developed using directional, rotational or orbital
cutting, or laser ablation of in-situ plaque, sometimes coupled with an aspiration system to actively remove debris and/
or mandating the use of a distal lter to collect this debris.
With several catheters having been removed from the market
temporarily for improvement or permanently due to failure
of concept, atherectomy devices have gradually evolved
towards a reduction in size prole and an increase in safety
and efcacy. However, the risk of complications such as dis-
N. Thulasidasan (*) · P. Gkoutzios
Interventional Radiology, Guys and St Thomas’ NHS Foundation
Trust, London, UK
e-mail: narayanan.thulasidasan@gstt.nhs.uk;
panos.gkoutzios@gstt.nhs.uk
tal embolization and vessel perforation remain an Achilles’
heel, and the relative paucity of randomized controlled data
regarding the additional worth conferred over balloon angioplasty alone has led to a lack of clarity over the precise role
of the technique within the endovascular armamentarium.
This, coupled with the high up-front cost of the devices has
limited their uptake among physicians treating peripheral
arterial disease.
Alongside the technical advancements, further understanding of the mode of action of atherectomy has resulted in
a paradigm shift in the philosophy of endovascular revascularization, with these devices now being applied to also perform ‘plaque modication’ (particularly in heavily calcied
atheroma) rather than simply relying on a plaque debulking
effect. Several non-atherectomy devices which also modify
plaque in different ways are now available, and together with
atherectomy these techniques are now grouped together as
‘vessel preparation’ modalities to be employed before the
delivery of denitive therapy with an angioplasty balloon
and/or stenting. The most promising non-atherectomy
calcium- modifying device to date is intravascular lithotripsy,
which will also be discussed.
Currently Available Atherectomy Devices
andEvidence forTheir Ecacy
Rotational Atherectomy
The Jetstream™ device from Boston Scientic is available in
four sizes (1.6mm, 1.85mm, 2.1mm and 2.4mm) and consists of ve front-cutting blades angulated to favour engaging harder diseased tissue whilst deecting away from the
softer tissues of the arterial wall, coupled with an active aspiration system to remove the generated debris. The two larger
catheters also contain expandable blades behind the tip
which increase luminal gain when opened to 3mm in the
2.1mm catheter and 3.4mm in the 2.4mm catheter (‘blades up’ mode). The catheters are single-use, but require connec-
© The Author(s), under exclusive license to Springer Nature Switzerland AG 2024
G. Geroulakos et al. (eds.), Mastering Endovascular Techniques, https://doi.org/10.1007/978-3-031-42735-0_19
181

182
https://t.me/medicina_free
N. Thulasidasan and P. Gkoutzios
tion to a reusable console which provides the power source
and saline pumping system for aspiration. The device has
been in clinical use for over a decade, with multiple singlecenter series published. The post-market JET registry
enrolled 241 patients with femoropopliteal lesions and
reported a 12-month freedom from TLR of 81.7%, [2] and
two prospective trials of the device in in-stent restenosis
returned sufciently positive results [3] that the device
received a CE marking for this indication.
A case example of Jetstream™ atherectomy for in-stent
restenosis is provided for illustration. An 81-year-old male
patient with past medical history of obesity, hypercholesterolaemia, hypertension, type 2 diabetes and ischemic heart
disease had (3months prior to presentation) stents inserted in
the left SFA and the proximal P1 popliteal artery segment to
aid healing of third and fourth toe amputations. On ultrasound duplex examination the stents were found to be
occluded and the patient underwent a transmetatarsal amputation together with a repeat endovascular procedure to
improve the blood supply for the wound to heal and prevent
below-knee amputation. Angiography demonstrated the
occluded stents (black arrows) and the peroneal artery was
the single run-off vessel (Fig.19.1). A 7-French sheath was
inserted antegrade in the left common femoral artery and for
embolic protection a SpiderFX™ lter was inserted distally
in the left popliteal artery (Fig. 19.2, red arrows). A
Jetstream™ 2.4 mm atherectomy device was employed
(Fig.19.2, black arrows) with two slow passes done with the
blades down followed by two slow passes with the blades up.
6mm in-stent plain balloon angioplasty was performed, but
due to residual stenosis (Fig.19.3) distal extension with two
Supera™ stents in the P2 and P3 popliteal segments, and
proximal extension in the left SFA with a drug-coated stent
(Zilver™ PTX) was required. The ow along the left femoropopliteal axis was restored, with preservation of patency of
the single-vessel tibial run-off (Fig.19.4).
The 2.2 mm, 1.8 mm and 1.5 Phoenix™ atherectomy
catheters from Philips utilize a front-cutting design with
blades that engage and cut into plaque, which is then passively cleared by means of passage through an Archimedes
screw system running along the entire internal length of the
catheter. The device is powered by a battery situated in the
handle, therefore no capital investment in a console is
required. The IDE trial revealed a 6-month freedom from
Fig. 19.1 Initial angiograms showing the left SFA and popliteal artery stents occluded (black arrows) and the distal single run off vessel, the
peroneal artery

19 Atherectomy andCalcium-Modifying Devices
https://t.me/medicina_free
Fig. 19.2 Guide wire
crossing the occluded stents,
lter placed in the popliteal
artery (its upper and lower
margins indicated with the
two red arrows) and
Jetstream™ rotational head
where the blades are
embedded (thick black
arrows)
183
Fig. 19.3 Images after the atherectomy and the plain balloon angioplasties, with remaining stenosis in the proximal left SFA (black arrow) and
the P2 popliteal artery segment (red arrow)

184
https://t.me/medicina_free
N. Thulasidasan and P. Gkoutzios
Fig. 19.4 Final angiograms, after additional stents were inserted in the proximal left SFA and the left popliteal artery. The peroneal and pedal
artery patency is preserved
TLR of 88%, [4] which was mirrored in a larger ‘real-world’
series of over 400 patients demonstrating freedom from TLR
of 87.5% (claudication) and 82.3% (chronic limb- threatening
ischaemia) and low rates of bail-out stenting [5].
balloon angioplasty or directional atherectomy with
SilverHawk™ or TurboHawk™ devices then drug-coated
balloon angioplasty. Although there was no signicant difference in primary patency via ultrasound at 1year in the atherectomy vs. no atherectomy group (84.6% vs. 81.3%), the
atherectomy group had a higher rate of technical success
Directional Atherectomy
dened as ≤30% residual stenosis following protocolassigned treatment (89.6% vs. 64.2%) and a lower rate of type
Directional atherectomy has undergone many iterative
improvements since the initial experience reported with the
Simpson atherectomy catheter by Höing etal. in 1987 [6].
The currently-available directional atherectomy catheters
include direct descendants of the Simpson device, namely
the ‘-Hawk’ family from Medtronic and the optical coherence tomography (OCT)-guided Pantheris™ from Avinger,
along with the 2.4 mm deecting and 2.2 mm deected
Phoenix™ atherectomy catheters from Philips.
The Hawk family (HawkOne™, SilverHawk™ and
TurboHawk™) and Pantheris™ devices mandate placement
of a distal lter, and collect plaque within a nosecone that
must be passed beyond the treatment segment and requires
removal each time it lls up with debris. The DEFINITIVE
AR study enrolled 102 patients Rutherford classes 2–4 and
randomized them 1:1 to treatment with plain then drug- coated
C/D dissection (2.1% vs. 18.5%) [7]. The REALITY study
was a physician-initiated multicentre trial enrolling 102
patients with calcied femoropopliteal lesions with mean
length of 17.9cm (39% chronic total occlusions), using the
HawkOne™ device and drug-coated balloon angioplasty. The
bail-out stenting rate was 8.8% and the 1-year primary
patency rate 76.7% in this challenging cohort [8].
The VISION trial enrolled 158 patients with 198 lesions
for treatment with the Pantheris™ device, returning a 93.6%
freedom from clinically-driven TLR rate at 6months, but
also demonstrating a reduction in stenosis down to 35.5%
after Pantheris™ treatment alone (i.e. before adjunctive
angioplasty) in the CTO subset and <1% advential content in
the removed debris [9]—hinting at the advantages in precision and 360° plaque clearance that real-time OCT guidance
might offer.

19 Atherectomy andCalcium-Modifying Devices
https://t.me/medicina_free
185
Orbital Atherectomy
The Stealth360™ device from Cardiovascular Systems Inc.
employs a small diamond-coated ‘crown’ mounted on a catheter that when activated orbits around a proprietary guidewire
in a 360° arc at very high speeds. The contact of the crown
with plaque causes a sanding effect to gain lumen, and the
generated particles of debris are considered to be small
enough to pass through capillaries i.e. their embolization
should be of no clinical consequence, and therefore no lter
placement is required. In the COMPLIANCE 360° TRIAL,
50 patients with calcied femoropopliteal atherosclerotic disease were randomized to treatment with balloon angioplasty
alone or orbital atherectomy plus balloon angioplasty, with a
signicantly lower bail-out stent rate seen in the orbital atherectomy group (5.3% vs. 77.8%) but a similar rate of freedom
from target lesion revascularization at 1 year (81.2% vs.
78.3%) [10]. The crowns for the Stealth360 device are available in a number of sizes going down to 1.25mm to treat
tibio-pedal vessels, and ongoing research aims to study the
safety and efcacy of this device in calcied distal disease.
Aspiration Atherothrombectomy
The Rotarex™ device from BD comes in 6-, 8- or 10-French
sizes and consists of two large side-facing distal windows
which aspirate occlusive material detached from the vessel
wall by catheter passage, fragment it within a system of highspeed rotating blades and then remove it from the body. There
is a capital outlay required for the drive system with a footpedal, but all the available Rotarex™ and Aspirex™ (thrombectomy) catheters are compatible with this unit. As with other
atherectomy devices level 1 evidence is limited, but there is a
growing body of case series suggesting the performance of
this device in removing the mixed-density thrombotic material
that builds up within occluded stents may warrant its preferred
use for this application, for example a retrospective multicentre analysis of 128 patients returning a primary clinical success/patency rate of 92.3% at 1year in iliofemoral in-stent
restenosis with a 5.5% distal embolization rate (all successfully treated endovascularly) [11]. However, the device has
also proven its effectiveness in management of native arterial
occlusion in both the acute and sub-acute settings, achieving a
technical success rate of 97.7%, (with 74.1% of patients maintaining their improvement in Rutherford class after one year
follow-up) in a large single-centre series of 525 consecutive
patients with mean lesion length of 159 mm [12].
Laser Atherectomy
There are two groups of laser atherectomy devices currently
on the market, the Turbo-Power/Turbo-Elite from Philips
and the Auryon™ from AngioDynamics, but both are characterized by requiring a relatively large console to generate
the laser beam, which confers a higher start-up cost than
other atherectomy devices.
The Philips group of catheters range from 0.9 to 2.5mm
in diameter, and utilize an excimer ultraviolet laser with uence of 30–60mJ/mm2 and repetition rate of 25–80Hz to
treat atheromatous plaque and in-stent restenosis by three
mechanisms: ablation from the light pulse of the laser itself,
a sonic wave which has theoretical effects on calcium within
the vessel wall and bursting of the formed vapour bubbles
which debulk and macerate mixed morphology plaque.
Filters are used at the discretion of the operator. The
EXCITE-ISR study was a prospective multicentre randomized control trial which conrmed that in a study population
of femoropopliteal lesions with mean length almost 20cm of
which around a third were total occlusions, laser atherectomy with the Turbo-Elite device resulted in a signicantly
better freedom from target lesion revascularization at
6months compared to plain balloon angioplasty (73.5% versus 51.8%, p<0.005) [13].
The Auryon system is a relative newcomer, using a smaller
base unit which can be plugged into a standard power socket
and generates a solid-state third harmonic pulsed Nd:YAG
laser with an output of 355nm. The laser catheters range in
size from 0.9 to 2.35mm; however, the 2mm and 2.35mm
catheters have a built-in aspiration system to reduce the risk
of distal embolization and the 2.35mm catheter incorporates
an off-centring mechanism to better target eccentric lesions.
Being a relatively novel device, there is limited clinical data
on its efcacy, with the EX-PAD-03 trial of 107 lesions in 97
patients (mean lesion length 5.4cm with 26.2% severely calcied and 79.4% de novo) demonstrating that laser use alone
resulted in a mean percentage stenosis reduction of 33.6%
with no distal embolization, and a very low rate of bail-out
stenting (0.9%). Patency was 96.8% at 30days, but long-term
follow-up of this cohort is awaited [14].
Indications forUse ofAtherectomy or Other
Calcium-Modifying Device
The decision for deployment of an atherectomy or other
calcium- modifying device during a revascularization procedure requires consideration of multiple factors. A thorough
analysis of the pre-operative imaging must be performed to
assess the plaque burden and characteristics, taking into
account lesion location, stenotic versus occlusive disease,
presence and severity of calcium and quality of the arterial
outow to the segment being targeted. Although atherectomy
or other calcium-modifying devices can technically be used
as a vessel-preparation tool in any patient, the operator
should be convinced that the arterial access is sufcient to

186
https://t.me/medicina_free
N. Thulasidasan and P. Gkoutzios
deliver the catheter to the target lesion, that use of the device
will confer an added benet over angioplasty alone and that
an embolic complication can be managed safely without risk
of severely compromising the patient’s outcome (e.g. treating the femoropopliteal segment in a patient with chronic
limb-threatening ischaemia who only has a single tibial runoff vessel).
A Cochrane review in 2020 suggested that the benecial
effects of atherectomy over angioplasty/stenting alone may
be limited to reduced dissection and need for bail-out stenting, although with the limited data available, the studies
included in the meta-analysis were small and considered to
be at high risk of bias [15]. A systematic review of 7 studies
including 497 patients treated with directional atherectomy
followed by drug coated balloon angioplasty in the common
femoral artery showed primary and secondary patency of
92% and 98% respectively at 1 year, with a 1–6% complication rate [16]. A systematic review of 6 studies with 470
patients concluded that the atherectomy combined with
drug-coated balloon angioplasty in the femoropopliteal segment decreased the need for bail-out stenting, compared to
the initial treatment with drug-coated balloon alone [17]. In
below-the-knee vessels, a systematic review including six
studies with a total of 1062 patients treated with different
atherectomy devices concluded that atherectomy in this territory has a high safety and efcacy prole and durable outcomes at 12months [18]. However, it recognized that in the
mid-term the clinical success of atherectomy was compromised by increased target lesion revascularization and major
adverse limb event rates, resulting in the conclusion that
compared to other endovascular techniques for below-theknee treatment, there is a slight lead of atherectomy at 1year
but equivalent clinical performance in the mid-term.
There is little head-to-head data comparing atherectomy
devices in the periphery, and none where device assignation
was randomized. Janas etal. suggested that the Phoenix™
device resulted in a lower rate of target lesion revascularization compared to SilverHawk™ in a single-centre retrospective analysis [19]. Wissgott etal. compared the Pathway™
device (precursor to the Jetstream™) with the Rotarex, but
the lesion length in the Rotarex group was more than twice
that in the Pathway group and therefore although the rate of
bail-out stenting, re-stenosis and complications were similar
between the two devices, little meaningful comparison can
be drawn from these data [20].
Given the paucity of high-quality data to justify routine
use, the authors choose to employ atherectomy primarily to
treat those chronic total occlusions in which the placement of
a stent is deemed particularly undesirable, for example,
younger patients, those with distal supercial femoral or
popliteal artery disease and those with suboptimal tibial
run-off.
Strategy andEndovascular Technique
Whilst atherectomy itself is very rarely painful if the catheter
is tracking intraluminally, use of atherectomy or other
calcium- modifying devices can increase procedure duration—particularly if distal embolization or vessel perforation
occurs. Therefore, consideration must be given to patient tolerance, and an appropriate plan for anaesthetic escalation
agreed and resourced prior to starting the procedure.
Ipsilateral antegrade common femoral artery is preferred
to maximize device pushability but in the case of ush supercial femoral artery (SFA) occlusions and/or short common
femoral artery (CFA) a contralateral groin puncture and
placement of an up-and-over sheath should be considered to
allow a safe approach to the lesion. The majority of femoropopliteal atherectomy catheters require a 0.014″ wire and a
7-French access sheath, so during treatment of the SFA origin there is a chance of the sheath accidentally displacing
completely out of the CFA potentially leaving only a smallcalibre guidewire in situ. If this occurs, the immediate priority is to cease running of the atherectomy device and
performing manual compression over the puncture site. The
atherectomy catheter can then be carefully withdrawn over
the 0.014″ guidewire, which is then serially upsized to 0.035″
to allow replacement of the original 7-French access sheath
(in our experience dedicated radial artery access sheaths will
frequently track through the soft tissues of the groin over the
0.014″ wire). If using a contralateral groin access, placing a
crossover sheath at least 1–2-French bigger than required for
the atherectomy catheter will ease device delivery over the
aortic bifurcation and improve control when the device is
running, particularly in the case of steep and/or calcied aortic bifurcations.
Lesion crossing must be intraluminal to safely use atherectomy. Not only does this reduce risk of the intra- procedural
perforation, but Tarricone etal. demonstrated a signicantly
increased risk of duplex-adjudicated restenosis at 1year in
patients with evidence of adventitial or medial injury in the
plaque removed following directional atherectomy versus
those without (97% vs. 11%) [21]. We strongly advocate the
use of intravascular imaging such as intravascular ultrasound
(IVUS) or optical coherence tomography (OCT) to conrm
intraluminal guidewire passage on a routine basis before
deciding to employ atherectomy. Note that if only a short
segment of the lesion crossing is subintimal, the remainder
of the intraluminal passage can be marked and safely treated
with atherectomy.
Once the lesion has been crossed, a lter can be placed if
mandated by the atherectomy device selected or desired by
the operator. The SpiderFX™ from Medtronic is mounted in
an off-centre-axis orientation onto a 0.014″ guidewire and is
available in 3–7mm diameters (suitable for placement in

19 Atherectomy andCalcium-Modifying Devices
https://t.me/medicina_free
187
vessels 2–7mm in diameter). As the lter element is attached
to the wire, it may be vulnerable to ‘wire-whip’ phenomenon, in which the rotational force from the activated atherectomy device causes rst the wire and then the lter to whip
and then spin, and may result in damage to the arterial wall
or trapping of the atherectomy device on to the lter-wire.
The Emboshield NAV6™ from Abbott (suitable for vessels
2.5–7mm in diameter) is separately advanced over a proprietary 0.014″ guidewire (BareWire™) into the desired position, and as it is not attached to the wire cannot be affected
by ‘wire-whip’. However, its maximum debris collection
volume is smaller and it requires several more steps to deploy
and re-capture than the SpiderFX™. Despite the theoretical
differences between the two devices, Krishnan etal. suggest
that there is no signicant difference in clinical outcome
between them when used with directional, rotational or laser
atherectomy [22].
Correct sizing of an atherectomy catheter may have an
important role to play reducing risk of complications and
improving clinical outcomes. Based on data from two RCTs,
most coronary atherectomy operators do not use cutting
devices larger than 60% of the reference vessel diameter [23,
24]. Although this phenomenon has not been assessed with
the same rigor in peripheral atherectomy, we believe the
same principles apply and therefore do not aggressively size
devices close to the reference vessel diameter.
With any atherectomy device, slow and steady advancement through the target lesion(s) is recommended to increase
effectiveness and reduce risk of complications. Slow
advancement allows cutting blades to engage with plaque to
achieve maximal cutting, rather than simply ‘Dottering’
through the lesion. In the case of the Jetstream™ device,
slow advancement also gives the active aspiration system
more time to clear debris before it can embolize. Alternating
1–2cm of advancement with a few milimetres of withdrawal
of the activated device can reduce the risk of the blades
becoming stuck within plaque. Orbital atherectomy devices
specically mandate a 30-s rest period for every 30 s of
treatment.
After completion of atherectomy treatment, repeat angiography and/or intravascular imaging is performed at the
operator’s discretion. If a lter has been used, this should be
inspected angiographically or exvivo for evidence of debris.
The lter should then be replaced beyond the atherectomized
segment before performing plain-balloon angioplasty with
or without adjunctive drug-coated balloon angioplasty.
Maintenance of a lter is important, as the atherectomy may
have introduced instability to plaques which remain in situ
but are vulnerable to fragmenting during the angioplasty
then embolizing after deation of the balloon. Further angiography and/or intravascular imaging is then performed to
assess for residual stenosis and ow-limiting dissection,
which can be further treated with bail-out stenting as deemed
appropriate for the severity of the residual lesion and the
clinical status of the patient.
Complications During Atherectomy
andTheir Management
The primary complication during atherectomy is distal
embolization. Both brotic and calcic atherosclerotic
plaque are vulnerable to fragmentation and embolization,
along with softer, more thrombotic components of chronic
total occlusions. The embolized material will frequently
lodge at a stenosis distal to the treatment segment, turning it
into an apparent occlusion on check angiography. The rst
sign of distal embolization may be a sudden distal ischaemic
lower-limb pain reported by the patient, or it may be clinically silent. If distal embolization is suspected, the rst two
priorities are to maintain patient comfort by upgrading analgesia if they are awake and to ensure that heparinization is
adequate to avoid thrombosis of the arteries distal to the
location of the embolus. Attention should then be turned to
mapping the location of the embolus to facilitate treatment.
Although angiography may show an abrupt cut-off of, e.g., a
tibial artery, crossing the cut-off point with a hydrophilictipped guidewire and advancing an appropriately sized catheter a short distance beyond the cut-off point to inject contrast
should localize the proximal and distal extent of the embolus.
Depending on the nature of the embolus, administration of a
small dose of recombinant tissue plasminogen activator may
be helpful in lysing thrombotic embolus or de novo thrombus
forming distally. However, if safe to do so, attempts to aspirate the thrombus with a catheter should be made. This is
achieved by advancing a catheter immediately beyond the
location of the embolus, attaching a 20mL Luer-lock syringe
to the catheter hub and applying negative pressure, then
immediately retracting the catheter slowly as the tip crosses
the location of the embolus and then more quickly to completely remove it from the body. A 6-French aspiration catheter is usually appropriate for the femoropopliteal segment;
however, a 4-French catheter may be required if embolus is
lodged in tibial arteries less than 2mm in diameter. Early and
generous local administration of isosorbide dinitrate is recommended to reduce spasm caused by rapid catheter manipulations during the aspiration manoeuvres. If the embolus
cannot be lysed or aspirated, balloon angioplasty of the segment where it has lodged can be performed, however there is
risk of fragmentation and more distal travel of these fragments into the pedal circulation. Multiple trashes of tiny
embolic particles into the pedal microcirculation can cause
the “no re-ow” phenomenon, in which the named tibiopedal
arteries are seen to be patent following atherectomy/angioplasty but with extremely sluggish ow. Catheter aspiration
cannot be employed here, and if on-table local thrombolysis

188
https://t.me/medicina_free
N. Thulasidasan and P. Gkoutzios
and nitrate administration is not successful in restoring brisk
ow, the patient may require a 12–24-h period of treatment
with an intravenous heparin infusion to allow some endogenous brinolysis and/or early distal collateralization to occur.
Perforation during atherectomy is rare unless the guidewire has taken a subintimal or extravascular course. It is frequently clinically silent and most often noticed incidentally
on check angiography post-atherectomy, however if left
untreated can sometimes progress to formation of thigh or
calf hematoma with potential risk of compartment syndrome
developing. After ensuring adequate heparinization, an
angioplasty balloon sized 1:1 to the arterial segment incorporating the extravasation is inated across the site of injury at
low (sub-nominal) pressure for three to 5min. The balloon is
then deated, removed and check angiography performed. If
the perforation has sealed then no further treatment is
required, however for persistent extravasation further lowpressure balloon ination or even covered stent placement
may be required.
Atherectomy devices may become stuck onto guidewires
during treatment. This can usually be avoided by careful
ushing of the device and maintaining adequate lubrication
of the external portions of the guidewire. If it occurs however, then the device may need to be removed en-bloc with
the guidewire, which also implies losing access to the lesion
crossing. In selected devices, ushing any lumen of the
atherectomy device that can be and running of the motor may
facilitate removal of the device over the wire. It is also possible for the blades of a rotational atherectomy device to
become stuck within a plaque. Again, this can be avoided
with careful technique, but if it occurs then applying rm
gentle traction to the device with the motor running can free
the blades without injuring the arterial wall.
(95% CI 53.30–65.31%) with minimal vascular complications [26]. However further high-quality evidence is required
to elucidate the efcacy of intravascular lithotripsy with
respect to different clinical characteristics such as lesion
location and length, and in comparison with other treatment
modalities such as atherectomy.
There are also several angioplasty-type devices available
which come under the generalized category of cutting or
scoring balloons, e.g., the Serranator balloons from Cagent
Vascular [27, 28]. Along with the atherotome Flex catheter
from VentureMed [29], these devices all work by causing
small longitudinal cuts in arterial plaque to better increase its
response to balloon angioplasty. The effectiveness and role
for these devices in the treatment of calcied plaque remains
under investigation.
Case Presentation
Continued from page 181
In view of the coral-reef proximal SFA plaque (Fig.19.5),
use of Jetstream™ atherectomy for calcium debulking and
plaque modication was chosen. With the patient under
sedation and local anaesthesia, the contralateral CFA was
punctured and an 8-French sheath advanced across the aortic
bifurcation to the distal right external iliac artery. The proximal SFA occlusion was crossed intraluminally (conrmed
with IVUS, Fig. 19.6), a lter placed beyond the lesion
Non-atherectomy Calcium-Modifying
Devices
The Shockwave™ intravascular lithotripsy system uses a
semi-compliant balloon-catheter containing multiple emitters to deliver acoustic pressure energy in a pulsatile fashion
to induce cracks in calcied atheroma. The compliance of
the calcium is thus increased, allowing the plaque to be more
effectively compressed towards the arterial wall when a noncompliant balloon is then inated across the lesion. The
DISRUPT-PAD III trial recently reported 2-year follow-up
data, revealing use of the Shockwave™ system in treatment
of a primarily claudicant population signicantly reduced
the requirement for bail-out stenting [25]. A meta-analysis of
9 studies including 681 patients concluded that intravascular
lithotripsy is an effective and safe approach for calcied
plaque modication in lower extremity peripheral arterial
disease, achieving a diameter stenosis reduction of 59.3%
Fig. 19.5 Flush right SFA occlusion demonstrated on angiography

19 Atherectomy andCalcium-Modifying Devices
https://t.me/medicina_free
(Fig. 19.7) and then two slow passes with a 2.4 mm
Jetstream™ catheter were made with the blades down, followed by two slow passes with the blades up. Repeat angiography showed debulking of calcium downstaging the
occlusion to a stenosis (Fig.19.8), along with a change in the
reverberation of the coral-reef plaque on IVUS (Fig.19.9).
189
Fig. 19.6 IVUS shows heavily calcied plaque with reverberation
artefact
Fig. 19.8 Post-atherectomy angiography conrms downstaging of the
occlusion to a stenosis
Fig. 19.7 The Jetstream™ catheter is advanced slowly through a
lesion. A 7mm SpiderFX™ lter is seen in the mid-SFA
Fig. 19.9 Post-atherectomy IVUS shows calcium debulking with visible lumen and reduced reverberation artefact

190
https://t.me/medicina_free
Fig. 19.10 Post-angioplasty angiography shows widely patent proximal SFA
Plain balloon angioplasty with a 7 mm balloon was performed, followed by retrieval of the lter. Check angiography revealed a widely patent proximal SFA (Fig.19.10) with
no evidence of perforation, dissection or distal embolization.
The distal SFA stenoses were treated uneventfully with
angioplasty and stent placement. After debridement of the
necrotic tissue, the patient’s foot wound healed
successfully.
References
1. Höing B, Pölnitz AV, Backa D, von Arnim T, Lauterjung L,
Jauch KW, etal. Percutaneous removal of atheromatous plaques in
peripheral arteries. Lancet. 1988;331(8582):384–6.
2. Gray WA, Garcia LA, Amin A, Shammas NW, JET Registry
Investigators. Jetstream atherectomy system treatment of femoropopliteal arteries: results of the post-market JET Registry.
Cardiovasc Revasc Med. 2018;19(5 Pt A):506–11.
3. Shammas NW, Jones-Miller S, Shammas GA, Shammas
JW. Jetstream atherectomy in treating femoropopliteal in-stent
restenosis: meta-analysis of the JETSTREAM-ISR and JET-ISR
trials. J Invasive Cardiol. 2020;32(8):289–94.
4. Davis T, Ramaiah V, Niazi K, Gissler HM, Crabtree T.Safety and
effectiveness of the Phoenix Atherectomy System in lower extremity arteries: early and midterm outcomes from the prospective multicenter EASE study. Vascular. 2017;25(6):563–75.
N. Thulasidasan and P. Gkoutzios
5. Giusca S, Hagstotz S, Lichtenberg M, Heinrich U, Eisenbach C,
Andrassy M, etal. Phoenix atherectomy for patients with peripheral
artery disease. EuroIntervention. 2022;18:e432.
6. Höing B, Backa D, von Arnim T, Jauch KW, Simpson JB.Method,
angiographic and clinical results of percutaneous atherectomy.
VASA Suppl. 1987;20:337–42.
7. Zeller T, Langhoff R, Rocha-Singh KJ, Jaff MR, Blessing E,
Amann-Vesti B, et al. Directional atherectomy followed by a
paclitaxel-coated balloon to inhibit restenosis and maintain vessel patency: 12-month results of the DEFINITIVE AR study. Circ
Cardiovasc Interv. 2017;10(9):e004848.
8. Rocha-Singh KJ, Sachar R, DeRubertis BG, Nolte-Ernsting CCA,
Winscott JG, Krishnan P, et al. Directional atherectomy before
paclitaxel coated balloon angioplasty in complex femoropopliteal
disease: the VIVA REALITY study. Catheter Cardiovasc Interv.
2021;98(3):549–58.
9. Schwindt AG, Bennett JG Jr, Crowder WH, Dohad S, Janzer SF,
George JC, etal. Lower extremity revascularization using optical
coherence tomography-guided directional atherectomy: nal results
of the EValuatIon of the PantheriS OptIcal COherence tomography
ImagiNg Atherectomy system for use in the peripheral vasculature
(VISION) study. J Endovasc Ther. 2017;24(3):355–66.
10. Dattilo R, Himmelstein SI, Cuff RF. The COMPLIANCE 360°
trial: a randomized, prospective, multicenter, pilot study comparing
acute and long-term results of orbital atherectomy to balloon angioplasty for calcied femoropopliteal disease. J Invasive Cardiol.
2014;26(8):355–60.
11. Loffroy R, Edriss N, Govault G, Chabanier A, Pernes J-M, Sauguet
A, etal. Percutaneous mechanical atherothrombectomy using the
Rotarex® S device in peripheral artery in-stent restenosis or occlusion: a French retrospective multicenter study on 128 patients.
Quant Imaging Med Surg. 2020;10(1):283–93.
12. Freitas B, Steiner S, Bausback Y, Branzan D, Ülrich M, Bräunlich
S, Schmidt A, Scheinert D. Rotarex mechanical debulking in acute
and subacute arterial lesions. Angiology 2017;68(3):233–241.
https://doi.org/10.1177/0003319716646682.
13. Dippel EJ, Makam P, Kovach R, George JC, Patlola R, Metzger C,
etal. Randomized controlled study of excimer laser atherectomy
for treatment of femoropopliteal in-stent restenosis: initial results
from the EXCITE ISR trial (EXCImer laser randomized controlled
study for treatment of FemoropopliTEal in-stent restenosis). JACC
Cardiovasc Interv. 2015;8(1 Pt A):92–101.
14. Shammas NW, Chandra P, Brodmann M, Weinstock B, Sedillo
G, Cawich I, et al. Acute and 30-day safety and effectiveness
evaluation of Eximo Medical’s B-Laser™, a novel atherectomy
device, in subjects affected with infrainguinal peripheral arterial
disease: results of the EX-PAD-03 trial. Cardiovasc Revasc Med.
2020;21(1):86–92.
15. Wardle BG, Ambler GK, Radwan RW, Hinchliffe RJ, Twine
CP.Atherectomy for peripheral arterial disease. Cochrane Database
Syst Rev. 2020;9(9):CD006680.
16. Usai MV, Lillu A, Asciutto G, Austermann MJ, Schwindt
AG.Systematic review of atherectomy of inguinal arteries for atherosclerotic lesions. J Cardiovasc Surg. 2022;63(1):2–7.
17. Lin F, Wang H, Ding W, Chen G, Zhang Z. Atherectomy plus
drug-coated balloon versus drug-coated balloon only for treatment
of femoropopliteal artery lesions: a systematic review and metaanalysis. Vascular. 2021;29(6):883–96.
18. Pitoulias AG, Pitoulias GA. The role of atherectomy in BTK
lesions: a systematic review. J Cardiovasc Surg. 2022;63(1):20–4.
19. Janas A, Milewski K, Buszman P, Kolarczyk-Haczyk A, Trendel
W, Pruski M, etal. Comparison of long-term outcomes after directional versus rotational atherectomy in peripheral artery disease.
Adv Interv Cardiol. 2020;16(1):76–81.
Соседние файлы в папке Библиотека им академика М.И. Перельмана
